[Dopaminergic Progenitor Cell Transplantation for Parkinson's Disease Treatment]
Nobukatsu Sawamoto1, Etsuro Nakanishi, Ryosuke Takahashi
1Department of Human Health Sciences, Kyoto University Graduate School of Medicine.
Abstract:
Human fetal ventral mesencephalic tissue transplantation provided early evidence supporting the efficacy of cell replacement therapy for Parkinson's disease; however, major challenges, including ethical concerns and graft-induced dyskinesia (GID), were raised. Recently, clinical trials using dopaminergic progenitor cells derived from induced pluripotent or human embryonic stem cells have demonstrated favorable safety profiles, graft survival, and the apparent absence of GID. Well-designed clinical trials are required to confirm the safety and establish its definitive clinical efficacy.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
EPS and iPS Cells in Disease Research
Parkinson's Disease: Overview
iPS Cell Differentiation


